Haemonetics Co. (NYSE:HAE) Shares Sold by F M Investments LLC

F M Investments LLC lowered its stake in Haemonetics Co. (NYSE:HAE) by 48.9% during the fourth quarter, Holdings Channel.com reports. The firm owned 52,339 shares of the medical instruments supplier’s stock after selling 50,133 shares during the quarter. F M Investments LLC’s holdings in Haemonetics were worth $4,087,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Thrivent Financial for Lutherans raised its holdings in Haemonetics by 14.9% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier’s stock valued at $98,716,000 after acquiring an additional 164,111 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Haemonetics by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,193,927 shares of the medical instruments supplier’s stock worth $95,986,000 after purchasing an additional 21,547 shares during the last quarter. Boston Trust Walden Corp grew its stake in shares of Haemonetics by 13.1% during the fourth quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier’s stock worth $71,500,000 after purchasing an additional 106,114 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in Haemonetics by 0.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 801,049 shares of the medical instruments supplier’s stock valued at $62,802,000 after buying an additional 5,668 shares during the last quarter. Finally, Fisher Asset Management LLC raised its stake in Haemonetics by 3.2% in the fourth quarter. Fisher Asset Management LLC now owns 711,774 shares of the medical instruments supplier’s stock valued at $55,575,000 after buying an additional 22,265 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Price Performance

Shares of NYSE:HAE opened at $59.18 on Friday. Haemonetics Co. has a one year low of $55.30 and a one year high of $97.97. The stock has a market capitalization of $2.97 billion, a price-to-earnings ratio of 23.30, a PEG ratio of 1.11 and a beta of 0.41. The company has a 50-day simple moving average of $63.78 and a 200-day simple moving average of $73.56. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. On average, analysts predict that Haemonetics Co. will post 4.55 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on HAE. Bank of America cut Haemonetics from a “neutral” rating to an “underperform” rating and lowered their price objective for the stock from $95.00 to $68.00 in a research report on Friday, February 7th. JMP Securities dropped their price target on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a research note on Friday, February 7th. Barrington Research reduced their price objective on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Needham & Company LLC dropped their target price on shares of Haemonetics from $108.00 to $104.00 and set a “buy” rating on the stock in a research report on Tuesday, March 18th. Finally, Raymond James reissued a “strong-buy” rating and issued a $115.00 price target (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Haemonetics currently has an average rating of “Moderate Buy” and a consensus price target of $101.22.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.